Optimi Health Corp.

Optimi Health Corp.

Optimi Health Strengthens Clinical and Regulatory Expertise

VANCOUVER, British Columbia, July 27, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), as part of its strategic aim to fully investigate the science of mushrooms, is pleased to announce the engagement of industry veteran Mr. John Simon to facilitate regulatory submissions and planning relevant t... Read More...

Optimi Health Joins First Psychedelic Exchange Traded Fund

VANCOUVER, British Columbia, July 13, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products is pleased to announce its inclusion in the first psychedelics Exchange Traded Fund (“ETF”) (NEO: PSYK). The ETF began trading on the Neo Exchange as of J... Read More...

Optimi Health Initiates Pathway to Nasdaq Listing

VANCOUVER, British Columbia, July 07, 2021 -- Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a vertically integrated developer of mushroom products announced today that it has engaged the consulting services of Donohoe Advisory Associates LLC (“Donohoe Advisory”) to explore strategies to advance towar... Read More...